vTv Therapeutics (VTVT) Research & Development (2014 - 2026)

vTv Therapeutics has disclosed Research & Development across 13 years of filings, most recently posting $9.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $9.0 million, up 217.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.0 million (up 104.73% YoY), and the FY2025 annual result was $17.9 million, up 54.69% from the prior year.
• Research & Development came in at $9.0 million for Q1 2026 at vTv Therapeutics, up from $3.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $9.0 million in Q1 2026 to a low of $2.1 million in Q4 2023.
• The 5-year median for Research & Development is $3.2 million (2024), against an average of $3.8 million.
• Across the five-year window, Research & Development plunged 46.06% in 2023 and soared 217.24% in 2026, its largest moves.
• vTv Therapeutics' Research & Development stood at $4.0 million in 2022, then slumped by 46.06% to $2.1 million in 2023, then increased by 4.49% to $2.2 million in 2024, then soared by 74.93% to $3.9 million in 2025, then jumped by 129.73% to $9.0 million in 2026.
• The last three Research & Development figures came in at $9.0 million (Q1 2026), $3.9 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.